Recommendations for a brief international cognitive assessment for multiple sclerosis (BICAMS)

Multiple Sclerosis Journal

Volumn 18, Issue 6, 2012, Pages 891-898

  Langdon, D W ^a   Amato, M P ^b   Boringa, J ^c   Brochet, B ^d   Foley, F ^e,m   Fredrikson, S ^f   Hamalainen P ^g   Hartung, H P ^h   Krupp, L ⁱ   Penner, I K ^j   Reder, A T ^k   Benedict, R H B ^l  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c MEANDER MEDICAL CENTER   (Netherlands)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e YESHIVA UNIVERSITY   (United States)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g Maskun Neurologinen Kuntoutuskeskus   (Finland)

^h HEINRICH HEINE UNIVERSITY   (Germany)

ⁱ ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^j UNIVERSITY OF BASEL   (Switzerland)

^k UNIVERSITY OF CHICAGO   (United States)

^l JACOBS NEUROLOGICAL INSTITUTE   (United States)

^m Holy Name Hospital   (United States)

more..

Author keywords

assessment; BVMT R; cognition information processing; CVLT II; memory; multiple sclerosis; neuropsychology; psychometrics; SDMT

Indexed keywords

BRIEF VISUOSPATIAL MEMORY TEST; CALIFORNIA VERBAL LEARNING TEST; CLINICAL ASSESSMENT; COGNITIVE ASSESSMENT; COGNITIVE DEFECT; CONSENSUS; DEPRESSION; FATIGUE; HUMAN; INFORMATION PROCESSING; MEDICAL EXPERT; MULTIPLE SCLEROSIS; PSYCHOLOGICAL RATING SCALE; REVIEW; SELF REPORT; SYMBOL DIGIT MODALITIES TEST; VERBAL MEMORY;

EID: 84861819610     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511431076     Document Type: Review

References (60)

1. Langdon DW. Cognition in multiple sclerosis. Curr Opin Neurol. 2011 ; 24: 244-249
2. Amato MP, Portaccio E, Goretti B, et al. Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study. Mult Scler. 2010 ; 16: 1474-1482
3. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology. 2008 ; 71: 632-638
4. Filippi M, Rocca MA, Benedict RH, et al. The contribution of MRI in assessing cognitive impairment in multiple sclerosis. Neurology. 2010 ; 75: 2121-2128
5. Langdon D. Cognitive impairment in multiple sclerosis-recent advances and future prospects. Eur Neurol Rev. 2010 ; 5: 69-72
6. Strober L, Englert J, Munschauer F, et al. Sensitivity of conventional memory tests in multiple sclerosis: comparing the Rao Brief Repeatable Neuropsychological Battery and the Minimal Assessment of Cognitive Function in MS. Mult Scler. 2009 ; 15: 1077-1084
7. Sumowski JF, Wylie GR, Chiaravalloti N, DeLuca J. Intellectual enrichment lessens the effect of brain atrophy on learning and memory in multiple sclerosis. Neurology. 2010 ; 74: 1942-1945
8. Kinsinger SW, Lattie E, Mohr DC. Relationship between depression, fatigue, subjective cognitive impairment, and objective neuropsychological functioning in patients with multiple sclerosis. Neuropsychology. 2010 ; 24: 573-580
9. Sherman TE, Rapport LJ, Ryan KA. Awareness of deficit in multiple sclerosis. J Clin Exp Neuropsychol. 2008 ; 30: 301-311
10. Benedict RH, Fischer JS, Archibald CJ, et al. Minimal neuropsychological assessment of MS patients: a consensus approach. The Clinical Neuropsychologist. 2002 ; 16: 381-397
11. Sicotte NL. Neuroimaging in multiple sclerosis: neurotherapeutic implications. Neurotherapeutics. 2011 ; 8: 54-62
12. Cheng EM, Crandall CJ, Bever CT, et al. Quality indicators for multiple sclerosis. Mult Scler. 2010 ; 16: 970-980
13. Rao SM A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis. Milwaukee, WI: Medical College of Wisconsin ; 1990 :
14. Marrie RA, Goldman M. Validity of performance scales for disability assessment in multiple sclerosis. Mult Scler. 2007 ; 13: 1176-1182
15. Aupperle RL, Beatty WW, Shelton Fde N, Gontkovsky ST. Three screening batteries to detect cognitive impairment in multiple sclerosis. Mult Scler. 2002 ; 8: 382-389
16. Langdon D, Amato M, Boringa J, et al. The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): first consensus steps towards a brief universal cognitive assessment for MS. Neurology. 2011 ; 76: A479
17. Christodoulou C, MacAllister WS, McLinskey NA, Krupp LB. Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?. CNS Drugs. 2008 ; 22: 87-97
18. Prakash RS, Snook EM, Lewis JM, Motl RW, Kramer AF. Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis. Mult Scler. 2008 ; 14: 1250-1261
19. Smith A Symbol Digit Modalities Test (SDMT) Manual. Los Angeles: Western Psychological Services ; 1982 :
20. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler. 2010 ; 16: 228-237
21. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Ann Neurol. 2000 ; 48: 885-92
22. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009 ; 8: 987-997
23. Benedict RH, Cookfair D, Gavett R, et al. Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc. 2006 ; 12: 549-558
24. Parmenter BA, Weinstock-Guttman B, Garg N, Munschauer F, Benedict RH. Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test. Mult Scler. 2007 ; 13: 52-57
25. Holmén C, Piehl F, Hillert J, et al. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis. Mult Scler. 2011 ; 17: 708-719
26. Deloire MS, Bonnet MC, Salort E, et al. How to detect cognitive dysfunction at early stages of multiple sclerosis?. Mult Scler. 2006 ; 12: 445-452
27. Portaccio E, Goretti B, Zipoli V, et al. Reliability, practice effects, and change indices for Rao's Brief Repeatable Battery. Mult Scler. 2010 ; 16: 611-617
28. Camp SJ, Stevenson VL, Thompson AJ, et al. Cognitive function in primary progressive and transitional progressive multiple sclerosis: a controlled study with MRI correlates. Brain. 1999 ; 122: 1341-1348
29. Benedict RH, Duquin JA, Jurgensen S, et al. Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire. Mult Scler. 2008 ; 14: 940-946
30. Morrow SA, Drake A, Zivadinov R, Munschauer F, Weinstock-Guttman B, Benedict RH. Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. The Clinical Neuropsychologist. 2010 ; 24: 1131-1145
31. Bomboi G, Ikonomidou VN, Pellegrini S, et al. Quality and quantity of diffuse and focal white matter disease and cognitive disability of patients with multiple sclerosis. J Neuroimag. 21 (2). e57-63
32. Houtchens MK, Benedict RH, Kiliiany R, et al. Thalamic atrophy and cognition in multiple sclerosis. Neurology. 2007 ; 18: 1213-1223
33. Brochet B, Deloire MS, Bonnet M, et al. Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study. Mult Scler. 2008 ; 14: 1242-1249
34. Mike A, Glanz BI, Hildenbrand P, et al. Identification and clinical impact of multiple sclerosis cortical lesions as assessed by routine 3T MR imaging. AJNR Am J Neuroradiol. 2011 ; 32: 515-521
35. Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimag. 2011 ; 21 (2). e50-6
36. Camp SJ, Stevenson VL, Thompson AJ, et al. A longitudinal study of cognition in primary progressive multiple sclerosis. Brain. 2005 ; 128: 2891-2898
37. Benedict RH, Ramasamy D, Munschauer F, Weinstock-Guttman B, Zivadinov R. Memory impairment in multiple sclerosis: correlation with deep grey matter and mesial temporal atrophy. J Neurol, Neurosurg Psychiat. 2009 ; 80: 201-206
38. Warlop NP, Achten E, Fieremans E, Debruyne J, Vingerhoets G. Transverse diffusivity of cerebral parenchyma predicts visual tracking performance in relapsing-remitting multiple sclerosis. Brain and Cognition. 2009 ; 71: 410-415
39. Einarsson U, Gottberg K, von Koch L, et al. Cognitive and motor function in people with multiple sclerosis in Stockholm County. Mult Scler. 2006 ; 12: 340-353
40. Delis DC, Kramer JH, Kaplan E, Ober BA California Verbal Learning Test. 2000. San Antonio, TX: Psychological Corporation ; 2000 :
41. Stegan S, Stepanov I, Cookfair D, et al. Validity of the California Verbal Learning Test-II in multiple sclerosis. The Clinical Neuropsychologist. 2010 ; 24: 189-202
42. Fink F, Eling P, Rischkau E, et al. The association between California Verbal Learning Test performance and fibre impairment in multiple sclerosis: evidence from diffusion tensor imaging. Mult Scler. 2010 ; 16: 332-341
43. J Neurol Sci. Sartori E Edan G, ed. 2006: 169-175.
44. Benedict RH, Bakshi R, Simon JH, Priore R, Miller C, Munschauer F. Frontal cortex atrophy predicts cognitive impairment in multiple sclerosis. J Neuropsych Clin Neurosci. 2002 ; 14: 44-51
45. Benedict RHB The Brief Visuospatial Memory Test Revised (BVMT-R). Lutz, FL: Psychosocial Assessment Resources Inc ; 1997 :
46. Rozewicz L, Langdon DW, Davie CA, Ron MA, Thompson AJ. Reversible focal cognitive impairment in multiple sclerosis. Cognitive Neuropsychiatry. 1996 ; 1: 17-25
47. Brunner R, Schaefer D, Hess K, Parzer P, Resch F, Schwab S. Effect of high-dose cortisol on memory functions. Ann NY Acad Sci. 2006 ; 1071: 434-437
48. Smith MM, Arnett PA. Dysarthria predicts poorer performance on cognitive tasks requiring a speeded oral response in an MS population. J Clin Exp Neuropsychol. 2007 ; 29: 804-812
49. Bruce JM, Bruce AS, Arnett PA. Mild visual acuity disturbances are associated with performance on tests of complex visual attention in MS. J Int Neuropsychol Soc. 2007 ; 13: 544-548
50. Boringa JB, Lazeron RH, Reuling IE, et al. The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice. Mult Scler. 2001 ; 7: 263-267
51. Amato MP, Portaccio E, Goretti B, et al. The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler. 2006 ; 12: 787-793
52. Oken BS, Flegal K, Zajdel D, et al. Cognition and fatigue in multiple sclerosis: Potential effects of medications with central nervous system activity. J Rehab Res Dev. 2006 ; 43: 83-90
53. Hindmarch I. Cognitive toxicity of pharmacotherapeutic agents used in social anxiety disorder. Int J Clin Prac. 2009 ; 63: 1085-1094
54. Dario A, Pisani R, Sangiorgi S, Pessina F, Tomei G. Relationship between intrathecal baclofen and the central nervous system. Acta Neurochir. 2007 ; 97: 461-464
55. Stephen LJ, Brodie MJ. Pharmacotherapy of epilepsy: newly approved and developmental agents. CNS Drugs. 2011 ; 25: 89-107
56. Ghaffar O, Feinstein A. Multiple sclerosis and cannabis: a cognitive and psychiatric study. Neurology. 2008 ; 71: 164-169
57. Rabinowitz AR, Arnett PA. A longitudinal analysis of cognitive dysfunction, coping, and depression in multiple sclerosis. Neuropsychology. 2009 ; 23: 581-591
58. Benedict RH, Cox D, Thompson LL, Foley F, Weinstock-Guttman B, Munschauer F. Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler. 2004 ; 10: 675-678
59. Krupp LB, Serafin DJ, Christodoulou C. Multiple sclerosis-associated fatigue. Expert Rev Neurother. 2010 ; 10: 1437-1447
60. Ebers GC, Reder AT, Traboulsee A, et al. Long-term follow-up of the original interferon-beta 1b trial in multiple scelrosis: design and lessons from a 16-year observational study. Clin Therap. 2009 ; 31: 1724-1736